Holen Sie sich die Stockscreener-App
1.21
2.54%
0.03
Handel nachbörslich:
1.20
-0.01
-0.83%
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
Institution Moves: Is TScan Therapeutics Inc. stock safe for conservative investorsOptions Play & Risk Adjusted Swing Trade Ideas - ulpravda.ru
Why TScan Therapeutics Inc. stock attracts global investorsRecession Risk & Reliable Breakout Stock Forecasts - ulpravda.ru
How institutional buying supports TScan Therapeutics Inc. stock2025 Trading Recap & Stepwise Trade Signal Implementation - ulpravda.ru
What risks investors should watch in TScan Therapeutics Inc. stock2025 Year in Review & Fast Exit/Entry Strategy Plans - ulpravda.ru
Why TScan Therapeutics Inc. stock is a must watch in 2025Weekly Stock Recap & Consistent Profit Trade Alerts - ulpravda.ru
Tech Rally: Why TScan Therapeutics Inc stock appeals to analysts2025 Stock Rankings & Proven Capital Preservation Methods - moha.gov.vn
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of “Hold” from Brokerages - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Guidance Update: Why TScan Therapeutics Inc stock attracts global investorsMarket Growth Review & Verified Swing Trading Watchlist - moha.gov.vn
Weekly Recap: Will West Fraser Timber Co Ltd stock see PE expansionTrade Volume Report & Growth-Oriented Investment Plans - moha.gov.vn
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Lynx1 Capital Management Lp Acquires 80,069 Shares - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Buys 75,500 Shares - MarketBeat
Is TScan Therapeutics Inc. stock dividend yield sustainableJuly 2025 PostEarnings & Weekly Breakout Watchlists - Улправда
TScan Therapeutics Earnings Notes - Trefis
How TScan Therapeutics Inc. stock reacts to oil pricesTrade Risk Assessment & AI Forecasted Entry/Exit Points - Улправда
Is TScan Therapeutics Inc. stock safe for conservative investorsJuly 2025 Sector Moves & Stepwise Trade Signal Implementation - DonanımHaber
Will TScan Therapeutics Inc. stock see PE expansionEarnings Miss & Community Consensus Stock Picks - DonanımHaber
TScan Therapeutics, Inc.(NasdaqGM: TCRX) dropped from NASDAQ Biotechnology Index - marketscreener.com
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event By Investing.com - Investing.com South Africa
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event - Investing.com Canada
TScan Therapeutics announces updated data from ALLOHA Phase 1 trial - MSN
TScan Therapeutics : ASH 2025 Virtual KOL Presentation - marketscreener.com
Wall Street analysts’ outlook for Tscan Therapeutics Inc (TCRX) - setenews.com
TCRX: TSC-101 shows durable efficacy and safety, with pivotal trial and market expansion set for next year - TradingView
TCRX: TSC-101 shows durable efficacy, safety, and $1.4B+ U.S. market potential in AML/MDS - TradingView — Track All Markets
Investor MeetingKey Opinion Leader - marketscreener.com
TScan Therapeutics Reports Promising Two-Year Relapse-Free Survival Data for TSC-101 in Phase 1 Trial for Hematologic Malignancies - Quiver Quantitative
TScan Therapeutics Announces Positive Updated Data from the - GlobeNewswire
How Low Can TScan Therapeutics Stock Really Go? - Trefis
TScan Therapeutics (TCRX) Price Target Increased by 10.53% to 7.14 - Nasdaq
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Is TScan Therapeutics Stock Built to Withstand a Pullback? - Trefis
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - KamloopsBCNow
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (2025-12-04) - Seeking Alpha
TScan to host KOL event discussing updated ALLOHA trial data By Investing.com - Investing.com Canada
TScan Therapeutics To Provide Update On Phase 1 Trial Of TSC-101 In Heme Malignancies Next Week - Nasdaq
TScan to host KOL event discussing updated ALLOHA trial data - Investing.com India
TScan Therapeutics to Host Virtual KOL Event on ALLOHA™ Phase 1 Trial Data and Market Opportunities - Quiver Quantitative
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities - The Manila Times
TScan Therapeutics, Inc. (TCRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Is TScan Therapeutics Inc a good long term investmentStock Liquidity Analysis & Free Tools to Find Winning Stocks - earlytimes.in
TScan Therapeutics Approves Key Employee Retention Program - The Globe and Mail
TScan Therapeutics ties executive pay to pivotal TSC-101 trial - Stock Titan
American Society of Hematology Meeting - marketscreener.com
Cluey Ltd Launches $4.5 Million Entitlement Offer - The Globe and Mail
Tscan Therapeutics Inc (TCRX) is looking forward to a strong quarter - Setenews
Reversal indicators forming on TScan Therapeutics Inc. stockProfit Target & Consistent Profit Alerts - newser.com
Is TScan Therapeutics Inc. stock positioned well for digital economyTrade Ideas & Daily Oversold Bounce Ideas - newser.com
Applying chart zones and confluence areas to TScan Therapeutics Inc.2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
Is TScan Therapeutics Inc. building a consolidation baseJuly 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):